Stifel raised the firm’s price target on Rapport Therapeutics (RAPP) to $56 from $35 and keeps a Buy rating on the shares after the company reported topline RAP-219 Phase 2a data in focal onset seizures that the firm says “clearly exceeded expectations.” The effect-size is “so large that we are increasingly confident” in the probability-of-success for the Phase 3 trial, the analyst tells investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPP:
- Morning Movers: EchoStar jumps following $17B spectrum deal with SpaceX
- Rapport Therapeutics price target raised to $34 from $31 at H.C. Wainwright
- Rapport Therapeutics Reports Positive Phase 2a Trial Results
- Rapport Therapeutics says Phase 2a trial of RAP-219 met primary endpoint
- Rapport Therapeutics plans to hold end-of-Phase 2 meeting with FDA in Q4